Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects
Department of Oncology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110003, China
Diagnostic Pathology 2013, 8:144 doi:10.1186/1746-1596-8-144Published: 23 August 2013
The Ser326Cys polymorphism in the human 8-oxogunaine glycosylase (hOGG1) gene with lung cancer susceptibility had been investigated, but results were inconsistent and underpowered. The aim of this study was to conduct a meta-analysis assessing the association of hOGG1 Ser326Cys polymorphism with risk of lung cancer.
Materials and methods
Relevant studies were identified through a search of MEDLINE, PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature database (CBM) using terms “lung cancer”, “hOGG1” or “OGG1”, “polymorphism” or “variation” and the last search updated on May 1, 2013. In this meta-analysis, we assessed 30 published studies involving 22,475 subjects that investigated the association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility.
Overall, the hOGG1 Ser326Cys polymorphism was not associated with lung cancer susceptibility in different genetic models (dominant model comparison: OR = 0.133; 95% CI = 0.111–0.161; Pheterogeneity = 0.000), and recessive model: OR = 0.543; 95% CI = 0.399–0.739; Pheterogeneity = 0.000). Similarly, in the stratified analyses by ethnicity, significantly increased risks were found among Asians for homozygote comparison (OR = 0.850; 95% CI = 0.732 0.986; Pheterogeneity = 0.064), and dominant model (OR = 0.160; 95% CI = 0.137–0.187; Pheterogeneity = 0.001), and Caucasians for dominant model (OR = 1.35; 95% CI = 1.03–1.77; Pheterogeneity = 0.015), and recessive model (OR = 1.35; 95% CI = 1.03–1.77; Pheterogeneity = 0.015). In population-based populations, marginally significant increased risks were found in dominant model (OR = 0.143; 95% CI = 0.111 0.184; Pheterogeneity = 0.000) and recessive model (OR = 0.429; 95% CI = 0.261–0.705; Pheterogeneity = 0.000). We also found a significant difference between hOGG1 Ser326Cys genotype and lung cancer susceptibility in studies with hospital-based controls for homozygote model (OR = 0.798; 95% CI = 0.649–0.982; Pheterogeneity = 0.007),dominant model (OR = 0.122; 95% CI = 0.091–0.163; Pheterogeneity = 0.000).
Our data showed that the hOGG1 Ser326Cys polymorphism contributed to the risk of lung cancer.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3842531131031605 webcite